Pharmaceuticals, Biotechnology and Life Sciences
Navamedic ASA said Thursday it grew revenues by 17% in the fourth quarter of 2020 compared to the same quarter last year, as it reported revenues of NOK 55.3 million in the fourth quarter of 2020 with an EBITDA of negative NOK 3.7 (€5.4) million driven by both new product launches and investments in further growth initiatives.
Novartis has received approval from the US Food and Drug Administration (FDA) after expanded indication for Entresto to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure.
Novavax and SK Bioscience, a vaccine business subsidiary of SK Group, today announced an expanded collaboration and license agreement to include for Bioscience a license to make and sell Novavax’ Covid-19 vaccine to the Korean government.
The drugs regulator in South Africa’s, SAHPRA, has approved an implementation study of Johnson & Johnson’s COVID-19 vaccine, it said…
Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has entered into an agreement to divest its Chinese research and development (R&D) subsidiary Basilea Pharmaceutica China Ltd. (“BPC”), by selling BPC’s parent company BPh Investitionen Ltd. to the U.S.-based custom manufacturing organization PHT International Inc. (“PHT”).
AstraZeneca on Thursday said it expects its 2021 revenue to grow after its COVID-19 vaccine success topped previous estimates for fourth-quarter sales.
Global contract development and manufacturing organisation (CDMO), Recipharm, has successfully extended its manufacturing license to include immunology products, allowing them to cater for customers’ vaccine products at clinical and commercial scales, in both freeze-dried and liquid forms.
Abzena announced they have been chosen to work with Immunome Inc. to produce IMM-BCP-01 for clinical testing – an investigational therapeutic antibody cocktail for the treatment of COVID-19 being developed to target multiple SARS-CoV-2 antigens.
WuXi STA has agreed to purchase Bristol Myers Squibb’s manufacturing facility in Couvet, Switzerland. The Couvet site will be the first facility in Europe for WuXi STA, a leading Contract Development and Manufacturing Organization. The acquisition will enhance WuXi STA’s existing capabilities while growing capacity to support its partners’ life-saving work.
The Carlyle Group (NASDAQ: CG), Brighton Park Capital and Indegene, the Bangalore-headquartered enterprise healthtech solutions provider, today announced that Carlyle…